While both unleash exhausted CD8 T cell responses, irrespective of the tumor type, anti-CTLA-4 antibodies additionally modulate the CD4 T cell effector compartment, by expanding an effector ICOS+ CD4 T cell subset [30]. Here, CD8A is linked to neoplasm.